Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Cash & Equivalents (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Cash & Equivalents for 13 consecutive years, with $7703.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 55.57% year-over-year to $7703.0, compared with a TTM value of $7703.0 through Nov 2025, down 55.57%, and an annual FY2025 reading of $15111.0, down 42.8% over the prior year.
  • Cash & Equivalents was $7703.0 for Q4 2025 at CNBX Pharmaceuticals, down from $15111.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.0 million in Q2 2021 and bottomed at $7703.0 in Q4 2025.
  • Average Cash & Equivalents over 5 years is $324114.8, with a median of $60577.0 recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 450.37% in 2021, then tumbled 97.25% in 2022.
  • Year by year, Cash & Equivalents stood at $786414.0 in 2021, then crashed by 97.25% to $21600.0 in 2022, then soared by 278.0% to $81647.0 in 2023, then plummeted by 78.76% to $17339.0 in 2024, then tumbled by 55.57% to $7703.0 in 2025.
  • Business Quant data shows Cash & Equivalents for CNBX at $7703.0 in Q4 2025, $15111.0 in Q3 2025, and $13648.0 in Q2 2025.